Open main menu

Wikipedia β

Particle therapy is a form of external beam radiotherapy using beams of energetic protons, neutrons, or positive ions for cancer treatment. The most common type of particle therapy as of 2012 is proton therapy. Although a photon, used in x-ray or gamma ray therapy, can also be considered a particle, photon therapy is not considered here. Additionally, electron therapy is generally put into its own category. Because of this, particle therapy is sometimes referred to, more correctly, as hadron therapy (that is, therapy with particles that are made of quarks).

Particle therapy
ICD-9 92.26

Neutron capture therapy might be considered a type of particle therapy, but it is not discussed here, as the damage it does to tumors is mostly from energetic ions produced by the secondary nuclear reaction after the neutrons in the external beam are absorbed into boron-10 (or occasionally some other nuclide), and not due primarily to the neutrons themselves. It is therefore a type of secondary particle therapy.

Muon therapy, a rare type of particle therapy not within the categories above, has occasionally been attempted.



Unlike electrons or X-rays, the dose from protons to tissue is maximum just over the last few millimeters of the particle’s range.

Particle therapy works by aiming energetic ionizing particles at the target tumor.[1][2] These particles damage the DNA of tissue cells, ultimately causing their death. Because of their reduced ability to repair damaged DNA, cancerous cells are particularly vulnerable to attack.

The figure shows how beams of electrons, X-rays or protons of different energies (expressed in MeV) penetrate human tissue. Electrons have a short range and are therefore only of interest close to the skin (see electron therapy). Bremsstrahlung X-rays penetrate more deeply, but the dose absorbed by the tissue then shows the typical exponential decay with increasing thickness. For protons and heavier ions, on the other hand, the dose increases while the particle penetrates the tissue and loses energy continuously. Hence the dose increases with increasing thickness up to the Bragg peak that occurs near the end of the particle's range. Beyond the Bragg peak, the dose drops to zero (for protons) or almost zero (for heavier ions).

The advantage of this energy deposition profile is that less energy is deposited into the healthy tissue surrounding the target tissue.

The ions are first accelerated by means of a cyclotron or synchrotron. The final energy of the emerging particle beam defines the depth of penetration, and hence, the location of the maximum energy deposition. Since it is easy to deflect the beam by means of electro-magnets in a transverse direction, it is possible to employ a raster scan method, i.e., to scan the target area quickly like the electron beam scans a TV tube. If, in addition, the beam energy and hence, the depth of penetration is varied, an entire target volume can be covered in three dimensions, providing an irradiation exactly following the shape of the tumor. This is one of the great advantages compared to conventional X-ray therapy.

At the end of 2008, 28 treatment facilities were in operation worldwide and over 70,000 patients had been treated by means of pions,[3][4] protons and heavier ions. Most of this therapy has been conducted using protons.[5]

At the end of 2013, 105 000 patients had been treated with proton beams,[6] and approximately 13, 000 patients had received carbon-ion therapy.[7]

As of April 1, 2015, for proton beam therapy, there are 49 facilities in the world, including 14 in the USA. with another 29 facilities under construction. For Carbon-ion therapy, there are eight centers operating and four under construction.[7] Carbon-ion therapy centers exist in Japan, Germany, Italy, and China. Two USA federal agencies are hoping to stimulate the establishment of at least one US heavy-ion therapy center.[7]

Proton therapyEdit

Fast-neutron therapyEdit

Carbon-ion radiotherapyEdit

Carbon ion therapy (CIRT) uses particles more massive than protons or neutrons. Carbon-ion radiotherapy has increasingly garnered scientific attention as technological delivery options have improved and clinical studies have demonstrated its treatment advantages for many cancers such as prostate, head and neck, lung, and liver cancers, bone and soft tissue sarcomas, locally recurrent rectal cancer, and pancreatic cancer, including locally advanced disease. It also has clear advantages to treat otherwise intractable hypoxic and radio-resistant cancers while opening the door for substantially hypo-fractionated treatment of normal and radio-sensitive disease.

By mid 2017, more than 15,000 patients have been treated worldwide in over 8 operational centers. Japan has been a conspicuous leader in this field. There are five heavy-ion radiotherapy facilities in operation and plans exist to construct several more facilities in the near future. In Germany this type of treatment is available at the Heidelberg Ion Therapy Center (HIT) and at Marburg University. In Italy the National Centre of Oncological Hadrontherapy (CNAO) provides this treatment. Austria will open a CIRT center in 2017, with centers in South Korea, Taiwan, and China soon to open. No CIRT facility now operates in the United States but several are in various states of development. [8]

Biological advantages of heavy-ion radiotherapyEdit

From a radiation biology standpoint, there is considerable rationale to support use of heavy-ion beams in treating cancer patients. All proton and other heavy ion beam therapies exhibit a defined Bragg peak in the body so they deliver their maximum lethal dosage at or near the tumor. This minimizes harmful radiation to the surrounding normal tissues. However, carbon-ions are heavier than protons and so provide a higher radiobiological effectiveness (RBE), which increases with depth to reach the maximum at the end of the beam's range. Thus the RBE of a carbon ion beam increases as the ions advance deeper into the tumor-lying region. [9] CIRT provides the highest linear energy transfer (LET) of any currently available form of clinical radiation. [10] This high energy delivery to the tumor results in many double-strand DNA breaks which are very difficult for the tumor to repair. Conventional radiation produces principally single strand DNA breaks which can allow many of the tumor cells to survive. The higher outright cell mortality produced by CIRT may also provide a clearer antigen signature to stimulate the patient's immune system. [11]


  1. ^ U. Amaldi and G. Kraft, "Radiotherapy with beams of carbon ions" in Rep. Progr. Physics 68 (2005) [pp.?] 1861, 1861–1882.
  2. ^ O. Jäkel, "State of the art in hadron therapy" in AIP Conference Proceedings vol. 958, no.1, 2007, pp. 70-77.
  3. ^ von Essen CF, Bagshaw MA, Bush SE, Smith AR, Kligerman MM (September 1987). "Long-term results of pion therapy at Los Alamos". Int. J. Radiat. Oncol. Biol. Phys. 13 (9): 1389–98. doi:10.1016/0360-3016(87)90235-5. PMID 3114189. 
  4. ^ "TRIUMF: Cancer Therapy with Pions". 
  5. ^ PTCOG: Particle Therapy Co-Operative Group
  6. ^ "". Retrieved 2015-06-01.  External link in |title= (help)
  7. ^ a b c Kramer, David (2015-06-01). "Carbon-ion cancer therapy shows promise". Physics Today. 68 (6): 24–25. doi:10.1063/PT.3.2812. ISSN 0031-9228. 
  8. ^ Hirohiko Tsujii, Overview of Carbon-ion Radiotherapy, IOP Conf. Series: Journal of Physics: Conf. Series 777,2017, 012032 doi:10.1088/1742-6596/777/1/012032
  9. ^ H. Tsujii, et. al., Carbon-Ion Radiotherapy; Principles, Practices and Treatment Planning, 2014 Japan; Springer-Verlag
  10. ^ K. Ando, et. al. 2005 J. Radiation Res. 2005, 46, p. 51
  11. ^ Daniel K. Ebner and Tadashi Kamada,The Emerging Role of Carbon-Ion Radiotherapy, Frontiers of Oncology, v.6, 2016; 2016PMC4894867

External linksEdit